NCT00618410 is a NA clinical trial of Carbon dioxide, USP in Allergic Rhinitis, sponsored by University of Chicago.

Who is sponsoring NCT00618410?

NCT00618410 is sponsored by University of Chicago.

What drugs are being tested in NCT00618410?

Interventions in NCT00618410: Carbon dioxide, USP, Placebo.

What condition does NCT00618410 study?

NCT00618410 studies Allergic Rhinitis.

Is NCT00618410 still recruiting?

NCT00618410 is currently completed. Last updated 9 December 2013.

Are results published for NCT00618410?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2013-12-09 · How we verify

NCT00618410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intranasal CO2 for Allergic Rhinitis

Completed NA Results posted Last updated 9 December 2013

What this trial tests

NA trial testing Carbon dioxide, USP in Allergic Rhinitis in 13 participants. Completed in 1 September 2008.

Timeline

1 February 2008

Primary endpoint
1 April 2008

1 September 2008

Quick facts

Lead sponsor	University of Chicago
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Enrollment	13
Start date	1 February 2008
Primary completion	1 April 2008
Estimated completion	1 September 2008
Sites	1 location across United States

Drugs / interventions tested

Carbon dioxide, USP — full drug profile →
Placebo

Conditions studied

Allergic Rhinitis — all drugs for Allergic Rhinitis →

Sponsor

University of Chicago

Who can join

Adults 18 to 45, any sex, with Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge
Time frame: 10 minutes post diluent challenge and 10 minutes post antigen challenge
Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into m

Sponsor's own description

The purpose of this study is to better understand the way in which CO2 (carbon dioxide) affects the symptoms of allergic rhinitis or hayfever. Our intent is to determine if CO2 has an effect on nasal challenge with antigen as a predictor of whether it will have a beneficial effect on the treatment of seasonal allergic rhinitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effect of intranasal carbon dioxide on the acute response to nasal challenge with allergen.
Baroody FM, Gavanescu L, Wang JH, DeTineo M, et al · · 2011 · cited 1× · PMID 21703101 · DOI 10.2500/aap.2011.32.3442

Verify or expand the search:

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00618410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 9 December 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00618410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing